Skip to main content
Clinical Trials/EUCTR2021-000429-28-DK
EUCTR2021-000429-28-DK
Active, not recruiting
Phase 1

Combined intravenous dexamethasone and dexmedetomidine as adjuncts to popliteal and saphenous nerve blocks in patients undergoing orthopaedic surgery of the foot and ankle. A randomised, blinded, placebo-controlled, parallel clinical trial.

Zealand University Hospital, Department of Anaesthesiology0 sites120 target enrollmentFebruary 19, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Participants undergoing osseous surgery of the foot or ankle with a popliteal and saphenous nerve blocks as means of providing anagelsia with general anaesthesia will be investigated.
Sponsor
Zealand University Hospital, Department of Anaesthesiology
Enrollment
120
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 19, 2021
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Zealand University Hospital, Department of Anaesthesiology

Eligibility Criteria

Inclusion Criteria

  • Scheduled for unilateral osseous surgery of the ankle or foot
  • General anaesthesia with both a popliteal and a saphenous nerve block for postoperative analgesia.
  • Age of 18 or above.
  • American Society of Anaesthesiologists Physical Status Score of 1 to 3\.
  • Body Mass Index of 18 to 40, but a minimum weight of 50 kg.
  • For fertile women, negative urine humane choriongonadotropine test or use of safe anti\-conception.
  • Ability to understand the trial protocol, risks, benefits, and provide signed informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes

Exclusion Criteria

  • Inability to read and understand Danish.
  • Uncooperativeness.
  • Participation in another trial involving medication.
  • Allergy to study medication.
  • Daily use of opioids above 30 mg/day morphine (or equivalents).
  • Daily use of corticosteroids of more than 5 mg prednisolone equivalents within the past one month.
  • Neurological or musculoskeletal disease making block performance impossible.
  • Dysregulated diabetes (as judged by investigators).
  • Dysregulated anticoagulants (as judged by investigators).
  • History of drug or alcohol abuse.

Outcomes

Primary Outcomes

Not specified

Similar Trials